{"id":67426,"date":"2026-06-05T13:53:33","date_gmt":"2026-06-05T05:53:33","guid":{"rendered":"https:\/\/flcube.com\/?p=67426"},"modified":"2026-06-05T13:53:35","modified_gmt":"2026-06-05T05:53:35","slug":"lonza-and-stipple-bio-forge-strategic-adc-partnership-combining-epitope-discovery-with-glyco-connect-platform-for-next-generation-oncology-therapies","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=67426","title":{"rendered":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Lonza<\/strong>, the Swiss <strong>Contract Manufacturing Organization (CMO)<\/strong>, announced a strategic licensing agreement with U.S.-based <strong>Stipple Bio<\/strong> to jointly develop <strong>next-generation precision oncology antibody-drug conjugate (ADC) therapies<\/strong>.<\/p>\n\n\n\n<h2 id=\"h-transaction-structure\" class=\"wp-block-heading\">Transaction Structure<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Parties<\/strong><\/td><td>Lonza (Switzerland) \/ Stipple Bio (United States)<\/td><\/tr><tr><td><strong>Agreement Type<\/strong><\/td><td>Licensing and development collaboration<\/td><\/tr><tr><td><strong>Primary Asset<\/strong><\/td><td>STP-100 and other ADC candidates with first-in-class and best-in-class potential<\/td><\/tr><tr><td><strong>Technology Integration<\/strong><\/td><td>Stipple Bio&#8217;s novel epitope discovery + Lonza&#8217;s Glyco Connect ADC platform<\/td><\/tr><tr><td><strong>Financial Terms<\/strong><\/td><td>Upfront payment + clinical, regulatory, and commercial milestone payments + royalties on net sales<\/td><\/tr><tr><td><strong>Manufacturing Responsibilities<\/strong><\/td><td>Lonza: proprietary technology components<br>Stipple Bio: research, development, manufacturing, and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-technology-synergy-amp-innovation\" class=\"wp-block-heading\">Technology Synergy &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Stipple Bio&#8217;s Contribution:<\/strong> <strong>Novel epitope discovery capabilities<\/strong> enabling identification of unique tumor-specific targets<\/li>\n\n\n\n<li><strong>Lonza&#8217;s Platform:<\/strong> <strong>Glyco Connect ADC platform<\/strong> \u2013 established technology for site-specific conjugation and optimized drug-to-antibody ratios<\/li>\n\n\n\n<li><strong>Lead Candidate:<\/strong> <strong>STP-100<\/strong> \u2013 ADC candidate with <strong>first-in-class and best-in-class potential<\/strong><\/li>\n\n\n\n<li><strong>Therapeutic Focus:<\/strong> <strong>Precision oncology<\/strong> targeting specific tumor antigens identified through Stipple&#8217;s discovery platform<\/li>\n\n\n\n<li><strong>Development Strategy:<\/strong> Leverages complementary expertise to accelerate ADC candidate progression from discovery to clinical development<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-competitive-landscape-analysis\" class=\"wp-block-heading\">Competitive Landscape Analysis<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Traditional ADC Development<\/th><th>Lonza-Stipple Collaboration<\/th><\/tr><\/thead><tbody><tr><td><strong>Target Identification<\/strong><\/td><td>Limited to known tumor antigens with variable specificity<\/td><\/tr><tr><td><strong>Conjugation Technology<\/strong><\/td><td>Heterogeneous conjugation leading to variable drug-to-antibody ratios<\/td><\/tr><tr><td><strong>Development Timeline<\/strong><\/td><td>3-5 years from target to IND<\/td><\/tr><tr><td><strong>Success Rate<\/strong><\/td><td>High attrition due to off-target toxicity and suboptimal efficacy<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-strategic-implications\" class=\"wp-block-heading\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Lonza&#8217;s Business Model Evolution:<\/strong> Expands beyond traditional CMO services into strategic partnerships with equity-like economics through milestone and royalty participation<\/li>\n\n\n\n<li><strong>Stipple Bio&#8217;s Advantage:<\/strong> Gains access to industry-leading ADC manufacturing technology without significant capital investment in manufacturing infrastructure<\/li>\n\n\n\n<li><strong>Market Positioning:<\/strong> Positions the partnership at the forefront of next-generation ADC development, competing with established players like Seagen, ImmunoGen, and Daiichi Sankyo<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Typical ADC partnerships generate $100-500 million in milestone payments plus 5-15% royalties on net sales for successful products<\/li>\n\n\n\n<li><strong>Pipeline Impact:<\/strong> Enables rapid expansion of both companies&#8217; ADC pipelines with multiple candidates leveraging the integrated platform<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-financial-framework\" class=\"wp-block-heading\">Financial Framework<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Payment Type<\/th><th>Recipient<\/th><th>Strategic Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>Upfront Payment<\/strong><\/td><td>Lonza<\/td><td>Immediate cash generation supporting platform investment<\/td><\/tr><tr><td><strong>Clinical Milestones<\/strong><\/td><td>Lonza<\/td><td>De-risked revenue tied to development progress<\/td><\/tr><tr><td><strong>Regulatory Milestones<\/strong><\/td><td>Lonza<\/td><td>Significant payments upon approval in major markets<\/td><\/tr><tr><td><strong>Commercial Milestones<\/strong><\/td><td>Lonza<\/td><td>Revenue linked to commercial success and market penetration<\/td><\/tr><tr><td><strong>Royalties<\/strong><\/td><td>Lonza<\/td><td>Long-term revenue stream from net product sales<\/td><\/tr><tr><td><strong>R&amp;D Investment<\/strong><\/td><td>Stipple Bio<\/td><td>Full responsibility for development costs and commercialization<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding strategic partnerships, technology integration, and development timelines. Actual results may differ due to risks including technical challenges, competitive developments, and regulatory considerations.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[35,678,4777],"class_list":["post-67426","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-adc-xdc","tag-lonza","tag-stipple-bio"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v27.7) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=67426\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies\" \/>\n<meta property=\"og:description\" content=\"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=67426\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-06-05T05:53:33+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-06-05T05:53:35+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies\",\"datePublished\":\"2026-06-05T05:53:33+00:00\",\"dateModified\":\"2026-06-05T05:53:35+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426\"},\"wordCount\":439,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"ADC \\\/ XDC\",\"Lonza\",\"Stipple Bio\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67426#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=67426\",\"name\":\"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-06-05T05:53:33+00:00\",\"dateModified\":\"2026-06-05T05:53:35+00:00\",\"description\":\"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=67426\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=67426#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry","description":"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=67426","og_locale":"en_US","og_type":"article","og_title":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies","og_description":"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.","og_url":"https:\/\/flcube.com\/?p=67426","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-06-05T05:53:33+00:00","article_modified_time":"2026-06-05T05:53:35+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=67426#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=67426"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies","datePublished":"2026-06-05T05:53:33+00:00","dateModified":"2026-06-05T05:53:35+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=67426"},"wordCount":439,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["ADC \/ XDC","Lonza","Stipple Bio"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=67426#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=67426","url":"https:\/\/flcube.com\/?p=67426","name":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-06-05T05:53:33+00:00","dateModified":"2026-06-05T05:53:35+00:00","description":"Lonza, the Swiss Contract Manufacturing Organization (CMO), announced a strategic licensing agreement with U.S.-based Stipple Bio to jointly develop next-generation precision oncology antibody-drug conjugate (ADC) therapies.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=67426#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=67426"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=67426#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Lonza and Stipple Bio Forge Strategic ADC Partnership \u2013 Combining Epitope Discovery with Glyco Connect Platform for Next-Generation Oncology Therapies"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67426","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=67426"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67426\/revisions"}],"predecessor-version":[{"id":67427,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/67426\/revisions\/67427"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=67426"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=67426"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=67426"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}